AR077864A1 - Microgranulos flotantes - Google Patents

Microgranulos flotantes

Info

Publication number
AR077864A1
AR077864A1 ARP100102964A ARP100102964A AR077864A1 AR 077864 A1 AR077864 A1 AR 077864A1 AR P100102964 A ARP100102964 A AR P100102964A AR P100102964 A ARP100102964 A AR P100102964A AR 077864 A1 AR077864 A1 AR 077864A1
Authority
AR
Argentina
Prior art keywords
carbonate
sodium
floating
chosen
group
Prior art date
Application number
ARP100102964A
Other languages
English (en)
Inventor
Christophe Lebon
Pascal Suplie
Original Assignee
Debregeas Et Associes Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debregeas Et Associes Pharma filed Critical Debregeas Et Associes Pharma
Publication of AR077864A1 publication Critical patent/AR077864A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Un granulado flotante que comprende un nucleo solido que da soporte a un principio activo como por ejemplo furosemida, nifedipina, metformina y que comprende también un compuesto susceptible de generar un desprendimiento gaseoso constituido por un agente alcalino, y procedimiento de preparacion del mismo. Reivindicacion 5: Granulado flotante de acuerdo con una cualquiera de las reivindicaciones 1 a 3, caracterizado porque el agente alcalino se elige entre el grupo constituido por carbonatos y bicarbonatos, y, en especial, se elige en el grupo constituido por bicarbonato de sodio, carbonato de sodio, carbonato de glicina de sodio, bicarbonato de potasio, carbonato de magnesio, carbonato de calcio.
ARP100102964A 2009-08-12 2010-08-12 Microgranulos flotantes AR077864A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0955641A FR2949061B1 (fr) 2009-08-12 2009-08-12 Microgranules flottants

Publications (1)

Publication Number Publication Date
AR077864A1 true AR077864A1 (es) 2011-09-28

Family

ID=42115979

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102964A AR077864A1 (es) 2009-08-12 2010-08-12 Microgranulos flotantes

Country Status (35)

Country Link
US (1) US8916202B2 (es)
EP (1) EP2464333B1 (es)
JP (1) JP6068142B2 (es)
KR (2) KR20120050477A (es)
CN (1) CN102548541B (es)
AR (1) AR077864A1 (es)
AU (1) AU2010283608B9 (es)
BR (1) BR112012003289B1 (es)
CA (1) CA2771053C (es)
CL (1) CL2012000376A1 (es)
CY (1) CY1118119T1 (es)
DK (1) DK2464333T3 (es)
EA (1) EA023532B1 (es)
ES (1) ES2588430T3 (es)
FR (1) FR2949061B1 (es)
HK (1) HK1172824A1 (es)
HR (1) HRP20161149T1 (es)
HU (1) HUE030027T2 (es)
IL (1) IL218072A (es)
IN (1) IN2012DN01864A (es)
LT (1) LT2464333T (es)
MA (1) MA33523B1 (es)
MX (1) MX2012001878A (es)
NZ (1) NZ598468A (es)
PE (1) PE20120805A1 (es)
PL (1) PL2464333T3 (es)
PT (1) PT2464333T (es)
SG (1) SG180305A1 (es)
SI (1) SI2464333T1 (es)
SM (1) SMT201600347B (es)
TN (1) TN2012000068A1 (es)
TW (1) TWI478731B (es)
UA (1) UA107361C2 (es)
WO (1) WO2011018582A2 (es)
ZA (1) ZA201201711B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
NZ581862A (en) 2007-05-25 2012-06-29 Tolmar Therapeutics Inc Injectable subcutaneous formulation comprising risperidone capable of forming a solid, microporous implant in a patient
FR2938431B1 (fr) 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US9321956B2 (en) 2012-11-28 2016-04-26 Halliburton Energy Services, Inc. Methods for hindering the settling of particulates in a subterranean formation
US9790774B2 (en) 2014-01-02 2017-10-17 Halliburton Energy Services, Inc. Generating and maintaining conductivity of microfractures in tight formations by generating gas and heat
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
WO2017018998A1 (en) 2015-07-24 2017-02-02 Halliburton Energy Services, Inc. Microbubbles for treatment chemical delivery in subterranean formations
WO2017018996A1 (en) 2015-07-24 2017-02-02 Halliburton Energy Services, Inc. Microbubbles for heat and/or gas generation in subterranean formations
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2019126218A1 (en) * 2017-12-18 2019-06-27 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
WO2019126215A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
NL2024652B1 (en) * 2020-01-10 2021-09-07 Stabican B V Process for preparing cannabinoid-containing particles
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276418A (en) * 1975-12-19 1977-06-27 Microbial Chem Res Found Method of preparing foamable micro-capsule preparations
US4101650A (en) * 1977-04-06 1978-07-18 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Pepstatin floating minicapsules
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
JPS62195323A (ja) * 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
IT1217783B (it) 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
IT1248588B (it) 1991-06-28 1995-01-19 Gaetano Crepaldi Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari.
IT1266565B1 (it) 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5824339A (en) 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6214386B1 (en) * 1995-11-22 2001-04-10 Recordati, S.A. Prompt-release oral pharmaceutical compositions for extemporaneous suspensions
US5846971A (en) 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
DE19630035A1 (de) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US6649186B1 (en) * 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
FR2762213B1 (fr) * 1997-04-18 1999-05-14 Synthelabo Composition pharmaceutique a retention gastrique
SE9702533D0 (sv) * 1997-07-01 1997-07-01 Astra Ab New oral formulation
JP3447042B2 (ja) 1997-07-23 2003-09-16 フロイント産業株式会社 単一物質球形粒の製造方法
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
JP4374441B2 (ja) 1998-12-23 2009-12-02 ジェイピーアイ コマーシャル，リミティド ライアビリティ カンパニー 睡眠発作治療のための、ガンマ−ヒドロキシ酪酸塩の微生物的に安全で安定な液剤
FR2797185B1 (fr) * 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
FR2823668B1 (fr) 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques Comprimes effervescents orodispersibles
KR20040060917A (ko) 2001-08-06 2004-07-06 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US20030059397A1 (en) 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
FR2829932B1 (fr) 2001-09-21 2006-11-24 Ellipse Pharmaceuticals Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs et produit obtenu
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
CA2497176A1 (en) 2002-09-04 2004-03-18 Ranbaxy Laboratories Limited Taste masked dosage forms and processes for their preparation
AU2003270778B2 (en) 2002-09-20 2009-10-08 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
US20050214371A1 (en) 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
TW200533391A (en) * 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
US8193211B2 (en) 2004-09-30 2012-06-05 Supernus Pharmaceuticals, Inc. Controlled release compositions of gamma-hydroxybutyrate
JP5095615B2 (ja) 2005-06-27 2012-12-12 バリアント・インターナショナル・（バルバドス）・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ ブプロピオン塩の放出調整製剤
PT1931315E (pt) * 2005-08-24 2014-01-03 Endo Pharmaceuticals Inc Formulações de libertação sustentada de nalbufina
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
WO2008134071A1 (en) 2007-04-26 2008-11-06 Theraquest Biosciences, Inc. Multimodal abuse resistant extended release formulations
EP1962844A2 (en) * 2005-12-20 2008-09-03 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
ZA200807571B (en) 2006-03-01 2009-08-26 Ethypharm Sa Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
US20090028941A1 (en) * 2007-07-27 2009-01-29 Depomed, Inc. Pulsatile gastric retentive dosage forms
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
FR2938431B1 (fr) 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments

Also Published As

Publication number Publication date
AU2010283608B2 (en) 2015-07-30
TWI478731B (zh) 2015-04-01
IL218072A (en) 2016-08-31
SMT201600347B (it) 2016-11-10
ES2588430T3 (es) 2016-11-02
CY1118119T1 (el) 2017-06-28
AU2010283608B9 (en) 2015-08-27
KR20170119743A (ko) 2017-10-27
CN102548541B (zh) 2015-03-11
FR2949061B1 (fr) 2013-04-19
JP2013501762A (ja) 2013-01-17
FR2949061A1 (fr) 2011-02-18
JP6068142B2 (ja) 2017-01-25
TN2012000068A1 (fr) 2013-09-19
EP2464333B1 (fr) 2016-06-29
HRP20161149T1 (hr) 2016-11-18
US20120207843A1 (en) 2012-08-16
WO2011018582A3 (fr) 2011-05-19
HUE030027T2 (en) 2017-04-28
ZA201201711B (en) 2012-11-28
EP2464333A2 (fr) 2012-06-20
CN102548541A (zh) 2012-07-04
SG180305A1 (en) 2012-06-28
UA107361C2 (en) 2014-12-25
IL218072A0 (en) 2012-04-30
CA2771053C (fr) 2017-05-02
WO2011018582A2 (fr) 2011-02-17
MA33523B1 (fr) 2012-08-01
US8916202B2 (en) 2014-12-23
LT2464333T (lt) 2016-09-12
KR20120050477A (ko) 2012-05-18
AU2010283608A1 (en) 2012-03-29
CL2012000376A1 (es) 2013-01-04
PL2464333T3 (pl) 2016-12-30
NZ598468A (en) 2015-05-29
BR112012003289B1 (pt) 2021-07-13
SI2464333T1 (sl) 2016-10-28
IN2012DN01864A (es) 2015-08-21
HK1172824A1 (en) 2013-05-03
PT2464333T (pt) 2016-10-03
PE20120805A1 (es) 2012-07-25
MX2012001878A (es) 2012-06-01
BR112012003289A2 (pt) 2020-08-11
TW201127419A (en) 2011-08-16
CA2771053A1 (fr) 2011-02-17
EA201200269A1 (ru) 2012-11-30
EA023532B1 (ru) 2016-06-30
DK2464333T3 (en) 2016-10-03

Similar Documents

Publication Publication Date Title
AR077864A1 (es) Microgranulos flotantes
AR085360A1 (es) GRANULADOS DE ACIDO g-HIDROXIBUTIRICO
ES2529725T3 (es) Combinaciones de principios activos nematicidas que comprenden fluopiram y Metarhizium
PE20120028A1 (es) Nueva composicion a base de acido gamma-hidroxibutirico
AR081549A1 (es) Formulaciones de polimeros alcalinos sin surfactante para recuperar petroleo crudo reactivo
PE20110893A1 (es) Formulacion farmaceutica que contiene 4-[3-(4-ciclopropanocarbonil-piperazina-1-carbonil)-4-fluorobencil]-2h-ftalazin-1-ona
ES2704264T3 (es) Espuma química que se aclara que contiene peróxido de benzoilo
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
PE20141821A1 (es) Composiciones herbicidas que contienen bentazon y el inhibidor als y el inhibidor accasa
AR047984A1 (es) Detergentes solidos para lavar la ropa con tensioactivo de amonio polianionico
CL2015002145A1 (es) Preparación, usos y formas sólidas de ácido obeticólico (divisional de solicitud n° 3475-2014)
AR081423A1 (es) Composiciones detergentes con contenido de lipasa de streptomyces griseus y metodos para utilizarlas
DOP2011000229A (es) Composicion farmaceutica solida que comprende amlodipina y losartan
PE20151786A1 (es) Compuestos heterociclicos y sus usos
UY35071A (es) ?formulación de forma farmacéutica sólida de desintegración veloz que comprende carbonato de calcio funcionalizado y método para su fabricación?.
PE20090605A1 (es) Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma
CO6460753A2 (es) Procedimiento y composición para mejorar la absorción de agentes terapéuticos
PE20130481A1 (es) Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona
MX2016015508A (es) Estabilidad de catalizador mejorada en formulaciones detergentes de peroxigeno activado y/o alcalino.
PE20121709A1 (es) Una composicion farmaceutica para tratar cancer que comprende tripsinogeno y/o quimotripsinogeno y un agente activo seleccionado a partir de un compuesto de selenio, un compuesto vainilloide y un agente reductor de glicolisis citoplasmica
CO6470893A2 (es) Agente y método de control para podredumbre blanda
PE20142043A1 (es) Enfoque metabolico selectivo para aumentar la biodisponibilidad oral de la fenilefrina y otros bioactivos metabolicos
CO6491056A2 (es) Composicion formadora de espuma para la generacion de señalizaciones de duración temporal acotada
WO2012045907A4 (es) Composiciones detergentes
AR084328A1 (es) Dispersiones acuosas de copolimero de etileno acido acrilico para liberacion de fragancia en detergentes de lavanderia

Legal Events

Date Code Title Description
FB Suspension of granting procedure